Searched for
RLL SHARES
India’s textile sector at an inflection point as global tariff barriers ease; Arvind Fashion, Raymond Lifestyle top buysThe immediate reduction in US tariffs on Indian textile goods from 50% to 18% has brought long-awaited relief to an industry that had been ...- Buy Raymond Lifestyle, target price Rs 3,000: Motilal Oswal Financial ServicesMotilal Oswal Financial Services recommends buying Raymond Lifestyle, targeting a price of Rs 3,000. Currently priced at Rs 2052.05, Raymon...
- Raymond Lifestyle shares rally 3% as Motilal Oswal predicts 29% upsideRaymond Lifestyle's shares rose 3.4% after Motilal Oswal projected a 29% upside, with a target of Rs 3,000. The growth outlook is fueled by...
- Motilal Oswal predicts 35% upside in Raymond Lifestyles, initiates coverage with ‘buy’ ratingMotilal Oswal has begun coverage of Raymond Lifestyle (RLL) with a buy rating and a target price of Rs 3,200, anticipating a transformative...
- Raymond Lifestyle shares list at Rs 3,020 on NSE after demergerRaymond Lifestyle Share Price: Raymond Lifestyle, which demerged from Raymond Ltd in June, began trading on the stock exchanges today. The ...
- Raymond shares surge 8% in 2 days ahead of lifestyle business’ listing tomorrowRaymond Share Price: Raymond's shares rose by 8% over two days, reaching Rs 2,179 on the BSE. This surge comes ahead of the listing of its ...
- Raymond shares jump 9% ahead of listing of lifestyle business. Here's whyRaymond Share Price: Raymond shares jumped 9% to Rs 2,182 ahead of its lifestyle business listing this week. Brokerages, including Motilal ...
- Raymond Lifestyle onboards top guns ahead of likely IPORaymond Lifestyle appointed Vineet Nayar, GC Chaturvedi, Anisha Motwani, and Dinesh Lal as directors. Gautam Singhania is likely MD, with S...
- Raymond shares trade ex-lifestyle business, stock jumps over 4%Raymond's lifestyle business demerger process begins with shareholders receiving new equity shares. The company's stock price rises by near...
- Ranbaxy launches anti-acne drug in the US marketAccording to an analyst, the launch of Absorica would greatly benefit Ranbaxy as there are only 2-3 players currently selling the product i...
- HDFC recommends 'sell' on Ranbaxy for target of Rs 230HDFC Securities has downgraded Ranbaxy Laboratories (RLL) from Hold to “Sell” with a price target of Rs 230 per share in its post-result up...
- CARE assigns 'PR1+' to bank loan facilities of RanbaxyCARE assigned 'PR1+' rating to the short term bank facilities availed by Ranbaxy Laboratories Ltd.
- Lupin buys Baroda co RubaminRLL, a subsidiary of the Rubamin group, manufactures advanced intermediates and Active Pharmaceutical Ingredients (APIs) and provides resea...
- Lupin acquires pharma business of RubaminDrug maker Lupin Ltd on Thursday said it has acquired the pharmaceutical business of Rubamin group, for an undisclosed amount.
- Ranbaxy launches 'Storvas' in MalaysiaThe company has received approvals from the Drugs Control Authority of Malaysia to manufacture and market the products.
Load More
